NEW
Livmarli

Livmarli

Manufacturer:

CANbridge

Distributor:

The Glory Medicina
/
DKSH
Concise Prescribing Info
Contents
Maralixibat
Indications/Uses
Cholestatic pruritus in patients ≥3 mth of age w/ Alagille syndrome.
Dosage/Direction for Use
Initially 190 mcg/kg once daily, increase to recommended dose 380 mcg/kg once daily, as tolerated, after 1 wk. Patient >70 kg Max daily dose vol: 3 mL or 28.5 mg.
Administration
Should be taken on an empty stomach: Administer 30 min before meal in the morning.
Special Precautions
Risk of liver test abnormalities; diarrhea, abdominal pain, & vomiting. Consider dose reduction or treatment interruption if liver abnormalities occur in the absence of other causes or if diarrhea, abdominal pain, &/or vomiting occur w/ no other etiologies found. May affect absorption of fat-soluble vit. Safety & effectiveness have not been established in patients <3 mth, elderly ≥65 yr, patients w/ clinically significant portal HTN & in patients w/ decompensated cirrhosis.
Adverse Reactions
Diarrhea, abdominal pain, vomiting, nausea, fat-soluble vit deficiency, increased transaminases (ALT, AST), GI bleeding, bone fractures.
Drug Interactions
Bile acid binding resins may bind to maralixibat in the gut. Potential decrease in oral absorption of OATP2B1 substrates (eg, statins).
MIMS Class
Cholagogues, Cholelitholytics & Hepatic Protectors
ATC Classification
A05AX04 - maralixibat chloride ; Belongs to the class of other drugs used in bile therapy.
Presentation/Packing
Form
Livmarli oral soln 9.5 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in